Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of “Buy” from Brokerages
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten analysts that are covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year […]
More Stories
Trump Designates Fentanyl as Weapon of Mass Destruction
By Darlene McCormick Sanchez President Donald Trump signed an executive order designating fentanyl as a weapon of mass destruction during...
Rob Reiner’s Son Booked for Murder After Director, Wife Found Dead
By Zachary Stieber Nick Reiner has been taken into custody following the death of his parents, Rob and Michele Reiner....
Tomorrow’s Jobs Report to Test the Resilience of the US Labor Market
By Andrew Moran The November jobs report will be released on Dec. 16, revealing the health of the U.S. labor...
US Officials Identify National Guardsmen Killed in ISIS Attack in Syria
By Jack Phillips The two U.S. military members killed over the past weekend in central Syria were Iowa Army National...
Police Detain Person of Interest in Deadly Brown University Shooting
By Jacob Burg A person of interest is in custody over the shooting at Rhode Island’s Brown University on Saturday...
Trump Honors US ‘Miracle on Ice’ Hockey Team in White House Celebration
By Travis Gillmore WASHINGTON—President Donald Trump hosted members of the 1980 U.S. Olympic hockey team at the White House on...